Part 1 examined ADHD as a prefrontal energy disorder. Part 2 examined the immune and neuroinflammatory strand. This part examines a third, distinct possibility: that a self-amplifying loop connects dopamine biology to the cell’s antioxidant-defense system and to the immune system’s central inflammatory switch.
This is not a fuel problem, and it is not simply an inflammatory problem. It is a feedback loop — a mechanism that, once set in motion, tends to sustain itself.
The series separates what we know from what our research adds. The established pieces are the dopamine-Nrf2 link (D1-receptor signaling enhances Nrf2 activity in cellular models) and the Nrf2 brake on NLRP3 inflammasome activation (via HO-1 and NQO1 induction), both drawn from the wider pharmacology and redox literature our project draws on, and discussed in a companion article on Nrf2-mediated hormesis. What our research adds is the specific cross-disease reading — that pre-existing low dopamine tone in ADHD lowers the threshold for post-infectious fatigue through this loop — which is a registered speculation, not an established finding.
The mechanism: a self-amplifying loop
The axis runs through three molecules:
1. Dopamine and Nrf2. Dopamine D1-receptor signaling enhances Nrf2 activity — via protein-kinase-A-mediated phosphorylation and nuclear import. Nrf2 is the master transcription factor of the cell’s antioxidant defenses, switching on over two hundred protective genes. When dopamine tone is low — as it is in ADHD — Nrf2-mediated antioxidant defenses are compromised, and the cell becomes more vulnerable to oxidative stress. A related route runs through dopamine-quinones: chronic low-grade dopamine oxidation produces reactive dopamine-quinone metabolites that deplete glutathione, further impairing Nrf2-driven antioxidant defense and disinhibiting the NLRP3 inflammasome in microglia and immune cells Sies (2017).
2. Nrf2 and NLRP3. Nrf2 normally suppresses the NLRP3 inflammasome, the immune system’s central inflammatory switch, via induction of HO-1 and NQO1. Reduced Nrf2 activity removes that brake. The NLRP3 inflammasome then drives elevated IL-1-beta and IL-18.
3. NLRP3 and dopamine — closing the loop. The elevated inflammation further impairs dopamine synthesis in two ways: it activates the IDO/kynurenine pathway, reducing the availability of BH4 for the enzyme that makes dopamine; and it induces oxidative stress that damages dopaminergic terminals. A further, more direct route runs through the kynurenine metabolite kynurenic acid, which at low concentrations reduces striatal dopamine release — connecting kynurenine overactivation straight to the dopamine deficit rather than only through the BH4 bottleneck Cysique et al. (2023). Lower dopamine → lower Nrf2 → more NLRP3 → more inflammation → even lower dopamine.
The result is a self-amplifying loop: a pre-existing low-dopamine state (as in ADHD) and a bout of inflammation each make the other worse, and the loop tends to persist.
The cross-disease bridge
The hypothesis that matters for ADHD is the lowered threshold for post-infectious fatigue. The mechanistic prediction is specific:
Individuals with ADHD have lower baseline Nrf2 activity and higher basal NLRP3 priming. This lowers the threshold for developing chronic fatigue after an infection. The elevated ADHD-to-chronic-fatigue comorbidity Sáez-Francàs et al. (2012) is a consequence of this pre-existing dopamine-Nrf2-NLRP3 dysregulation.
In plain terms: a person with ADHD starts with the loop already tilted toward inflammation. When an infection adds an inflammatory hit, the loop tips further, and the person is more likely to cross the fatigue threshold than someone without that pre-existing tilt.
This is the same BH4 bottleneck our project has explored across conditions — the cofactor that inflammation diverts away from dopamine synthesis and toward a different branch of its metabolism. The loop is one way of describing why that single bottleneck matters so widely.
Where a mechanism already has a dedicated article
Two dedicated articles carry the established groundwork this part builds on:
- The Inverted-U Is Not One Thing — the Nrf2-mediated hormesis mechanism, the Keap1-Nrf2-ARE pathway, and why Nrf2 drugs (LDN, sulforaphane, quercetin) work only in a narrow dose window. This part does not repeat that content; it extends it to the cross-disease ADHD axis.
- One Cofactor, Six Conditions, One Bottleneck — the BH4 cofactor that inflammation diverts away from dopamine synthesis.
The Nrf2/NLRP3 axis described here is our reading of how those established mechanisms behave in an ADHD-affected, infection-stressed brain. The underlying pharmacology is established; the ADHD-specific cross-disease claim is a registered speculation.
A genetic strand: ADHD’s own architecture, and shared mitochondrial modifiers
Before the cross-disease reading, ADHD has its own well-established genetic architecture, independent of any connection to chronic fatigue. It is among the most heritable of psychiatric conditions.
ADHD’s own genetics. The largest genome-wide study of ADHD — nearly forty thousand cases — identified 27 genome-wide significant risk loci, up from 12 in earlier studies, implicating genes expressed in the brain and in cognitive domains (Demontis et al. 2023). Family and twin studies place its twin-based heritability high — around seventy to eighty percent (Faraone and Larsson 2019). Twin studies confirm that genetic influences on ADHD and autism are substantially shared and are among the strongest genetic correlations in psychiatry (Polderman et al. 2014). Genome-wide studies find a genetic correlation around 0.35–0.41 between ADHD and autism Grove et al. (2019), and when five major psychiatric disorders are analyzed together, ADHD and autism cluster as a single neurodevelopmental group, genetically distinct from the psychotic and mood group (Cross-Disorder Group of the Psychiatric Genomics Consortium 2013). Twin studies confirm this overlap is present from childhood and persists into adulthood Polderman et al. (2014). This is why ADHD and autism co-occur far beyond chance — a meta-analysis found a pooled ADHD prevalence of 28% in autism (Lai et al. 2019), and a register study of nearly two million births found an autism diagnosis elevated the odds of ADHD roughly 22-fold (Ghirardi et al. 2018).
This standalone genetic picture matters for the series because it grounds the “what we know” side: the metabolic hypotheses in Parts 1–3 are added onto a well-replicated genetic and neurobiological foundation, not invented in its place.
One genuinely open question from our paper deserves a flag here: the genetic correlation between ME/CFS itself and ADHD has not been computed. If it turned out to be substantial, it would support the dopamine signal in the chronic-fatigue genome and raise whether childhood ADHD is a direct genetic risk factor for post-infectious fatigue — rather than only a metabolic one. This is an open question, not a finding.
Shared mitochondrial modifiers
The cross-disease reading also has a genetic strand. Two hypotheses from our paper connect ADHD and chronic fatigue at the level of the mitochondrial genome.
Haplogroup U as a shared modifier. Mitochondrial haplogroup U appears as a modifier in both conditions independently: in a meta-analysis of over two thousand ADHD cases, haplogroup U (and K) was protective against an ADHD diagnosis (Chang et al. 2020); in a chronic-fatigue cohort, the same haplogroup was associated with attenuated symptom severity (Billing-Ross et al. 2016). This single cross-study overlap suggests — speculatively — that haplogroup U confers a mitochondrial bioenergetic configuration protective across both conditions, with the specific phenotype depending on which system is stressed most: prefrontal dopaminergic dysfunction in ADHD, or whole-body metabolic collapse in chronic fatigue. The broader ADHD mitochondrial-genetics field is real but underdeveloped: a systematic review documents haplogroup effects, elevated mtDNA copy number, and SNP associations across ADHD populations, while noting the primary studies are small and methodologically heterogeneous (Giannoulis et al. 2024). Even so, no study has yet measured haplogroup, ADHD comorbidity, and chronic fatigue in one cohort, so the cross-disease haplogroup-U reading remains a registered speculation.
Constitutional low-capacity mitochondria. A complementary framing inverts the demand side: instead of (or alongside) higher energy demand, neurodivergent brains may carry genetically lower-capacity mitochondria. The same alleles that produce beneficial cognitive traits — rapid pattern recognition, hyperfocused attention, sensory acuity — may be pleiotropically linked to mitochondrial variants that trade coupling efficiency for membrane flexibility or rapid remodeling. ADHD shows direct evidence of mitochondrial bioenergetic impairment: cybrid cell lines from ADHD patients’ platelets show lower respiration, reduced ATPase activity, and elevated oxidative stress, and these defects transfer with the patient’s own mitochondria Almutairi et al. (2024). If the reduced reserve is constitutional — encoded in the genome and present from birth — it would explain why a person with ADHD starts closer to the fatigue threshold before any infection. This is a registered speculation, not an established finding.
The testable predictions
Because this hypothesis is mechanistic, it makes specific, falsifiable predictions:
- Chronic-fatigue patients with ADHD comorbidity show lower Nrf2 nuclear translocation in their peripheral blood mononuclear cells than chronic-fatigue patients without ADHD.
- NLRP3 inflammasome markers (IL-1-beta, caspase-1 activity) are elevated in the comorbid group relative to chronic fatigue alone.
- Nrf2-activating interventions (sulforaphane, dimethyl fumarate) improve both ADHD symptoms and fatigue in the comorbid group.
- Nrf2 promoter polymorphisms predict post-infectious fatigue severity in ADHD cohorts.
- Stimulant exposure provokes inflammation in the comorbid group: our paper’s dopamine-quinone reading predicts that stimulants (which raise dopamine and accelerate its oxidation to quinones) would increase IL-1-beta via NLRP3 in blood-cell cultures from ADHD-comorbid patients, and that this effect would be blocked by Nrf2 agonists or NLRP3 inhibitors. This also sharpens the warning that stimulants are not a free pass in this group — a prediction about a mechanism that could contribute to post-exertional worsening.
Each prediction is testable with existing assays and existing cohorts. None has been run.
The honest limits
This is a speculative hypothesis, with explicit low confidence — a registered speculation, not an established finding.
- The D1-receptor–Nrf2 link is established in cellular models but not in human patients.
- Nrf2 pathway activity has been measured in ADHD patients only once, in a 2026 study of 60 adults with ADHD versus 60 controls, which found serum Nrf2 and HO-1 protein significantly reduced in ADHD and negatively correlated with symptom severity (Gürbüzer, Ozkaya, and Mercantepe 2026). This is consistent with — but does not establish — the axis proposed here: it measured circulating serum protein, not Nrf2 nuclear translocation or NQO1 target-gene expression, and it is adult ADHD only, a single study.
- No study has measured Nrf2 nuclear translocation or NQO1 expression in ADHD cells.
- No prospective ADHD-to-fatigue longitudinal data exist that test the inflammation-mediation chain directly.
- Comorbidity estimates are confounded by diagnostic overlap in symptom reporting.
- Nrf2/NLRP3 crosstalk is well characterized in redox biology, but the cross-disease claim — that ADHD’s pre-existing state specifically lowers the fatigue threshold — is an inference, not a measurement.
The loop is mechanistically plausible and each link has support in isolation, but the chain as a whole is untested.
What to take away
The dopamine-Nrf2-NLRP3 axis offers a self-amplifying loop explanation for a striking pattern: people with ADHD get chronic fatigue at roughly twice the rate, and the elevated risk is mediated by inflammation. It connects three things — dopamine, antioxidant defense, and the inflammatory switch — that are usually studied separately.
Unlike Part 1, this strand does not yet point to a tested intervention. Nrf2-activating agents such as sulforaphane exist and are mechanistically plausible, but no trial has tested them against the ADHD-fatigue axis specifically. Its value is explanatory and predictive: it names a specific, measurable loop and a set of testable predictions.
The encouraging part: the predictions are cheap and testable with existing assays. If they hold, they give the ADHD-to-fatigue association a concrete biological mechanism. If they fail, they narrow the search.
This is Part 3 of a four-part series on the biology of ADHD. Part 1 covers the prefrontal-energy model and the multi-pathway treatment hypothesis. Part 2 covers the immune and neuroinflammatory strand. Part 4 asks when ADHD-like features are acquired and reversible. See the series landing page.
This article reflects a registered research hypothesis with low confidence, not established clinical fact.
References
Almutairi, Mohammed M, Abdulrahman Althekair, Fahad Almutairi, Mohammed Alatabani, and Abdulaziz Alsaikhan. 2024.
“Mitochondrial Dysfunction and Mitophagy in ADHD: Cellular and Molecular Mechanisms.” Saudi Pharmaceutical Journal 32 (12): 102212.
https://doi.org/10.1016/j.jsps.2024.102212.
Billing-Ross, Paul, Arnaud Germain, Ketian Ye, Alon Keinan, Zhenglong Gu, and Maureen R Hanson. 2016.
“Mitochondrial DNA Variants Correlate with Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Translational Medicine 14: 19.
https://doi.org/10.1186/s12967-016-0771-6.
Chang, Xiao, Yichuan Liu, Frank Mentch, Joseph Glessner, Huiqi Qu, Kenny Nguyen, Patrick M A Sleiman, and Hakon Hakonarson. 2020.
“Mitochondrial DNA Haplogroups and Risk of Attention Deficit and Hyperactivity Disorder in European Americans.” Translational Psychiatry 10: 370.
https://doi.org/10.1038/s41398-020-01064-1.
Cross-Disorder Group of the Psychiatric Genomics Consortium. 2013.
“Genetic Relationship Between Five Psychiatric Disorders Estimated from Genome-Wide SNPs.” Nature Genetics 45 (9): 984–94.
https://doi.org/10.1038/ng.2711.
Cysique, Lucette A., David Jakabek, Stephanie G. Bracken, Yana Allen-Davidian, Benjamin Heng, Simone Chow, Mona Dehhaghi, et al. 2023.
“The Kynurenine Pathway Relates to Post-Acute COVID-19 Objective Cognitive Impairment and PASC.” Annals of Clinical and Translational Neurology 10 (8): 1338–52.
https://doi.org/10.1002/acn3.51825.
Demontis, D., G. B. Walters, G. Athanasiadis, R. Walters, K. Therrien, T. T. Nielsen, L. Farajzadeh, et al. 2023.
“Genome-Wide Analyses of ADHD Identify 27 Risk Loci, Refine the Genetic Architecture and Implicate Several Cognitive Domains.” Nature Genetics 55 (2): 198–208.
https://doi.org/10.1038/s41588-022-01285-8.
Faraone, S. V., and H. Larsson. 2019.
“Genetics of Attention Deficit Hyperactivity Disorder.” Molecular Psychiatry 24 (4): 562–75.
https://doi.org/10.1038/s41380-018-0070-0.
Ghirardi, L., I. Brikell, R. Kuja-Halkola, C. M. Freitag, B. Franke, P. Asherson, P. Lichtenstein, and H. Larsson. 2018.
“The Familial Co-Aggregation of ASD and ADHD: A Register-Based Cohort Study.” Molecular Psychiatry 23 (2): 257–63.
https://doi.org/10.1038/mp.2017.17.
Giannoulis, Stavroula V, Daniel Müller, James L Kennedy, and Vanessa Gonçalves. 2024.
“Systematic Review of Mitochondrial Genetic Variation in Attention-Deficit/Hyperactivity Disorder.” European Child & Adolescent Psychiatry 33 (6): 1675–85.
https://doi.org/10.1007/s00787-022-02030-6.
Grove, J., S. Ripke, T. D. Als, M. Mattheisen, R. K. Walters, H. Won, J. Pallesen, et al. 2019.
“Identification of Common Genetic Risk Variants for Autism Spectrum Disorder.” Nature Genetics 51 (3): 431–44.
https://doi.org/10.1038/s41588-019-0344-z.
Gürbüzer, Nazan, Ahmet Ozkaya, and Filiz Mercantepe. 2026.
“The SIRT-1/Nrf-2/HO-1 Antioxidant Defense Axis in Adult Attention-Deficit/Hyperactivity Disorder.” Metabolic Brain Disease 41 (1).
https://doi.org/10.1007/s11011-026-01845-5.
Lai, Meng-Chuan, Caroline Kassee, J. Besney, S. Bonato, L. Hull, W. Mandy, P. Szatmari, and S. H. Ameis. 2019.
“Prevalence of Co-Occurring Mental Health Diagnoses in the Autism Population: A Systematic Review and Meta-Analysis.” The Lancet Psychiatry 6 (10): 819–29.
https://doi.org/10.1016/S2215-0366(19)30289-5.
Polderman, T. J. C., R. A. Hoekstra, D. Posthuma, and H. Larsson. 2014.
“The Co-Occurrence of Autistic and ADHD Dimensions in Adults: An Etiological Study in 17,770 Twins.” Translational Psychiatry 4: e435.
https://doi.org/10.1038/tp.2014.84.
Quadt, Lisa, Jenny Csecs, Robert Bond, et al. 2024.
“Childhood Neurodivergent Traits, Inflammation and Chronic Disabling Fatigue in Adolescence: A Longitudinal Case-Control Study.” BMJ Open 14 (7): e084203.
https://doi.org/10.1136/bmjopen-2024-084203.
Rassoulpour, Asma, Hui-Qiu Wu, Sergi Ferré, and Robert Schwarcz. 2005.
“Nanomolar Concentrations of Kynurenic Acid Reduce Extracellular Dopamine Levels in the Striatum.” Journal of Neurochemistry 93 (3): 762–65.
https://doi.org/10.1111/j.1471-4159.2005.03134.x.
Ronald, A., E. Simonoff, J. Kuntsi, P. Asherson, and R. Plomin. 2008.
“Evidence for Overlapping Genetic Influences on Autistic and ADHD Behaviours in a Community Twin Sample.” Journal of Child Psychology and Psychiatry 49 (5): 535–42.
https://doi.org/10.1111/j.1469-7610.2007.01757.x.
Sáez-Francàs, Naia, José Alegre, Neus Calvo, et al. 2012.
“Attention-Deficit Hyperactivity Disorder in Chronic Fatigue Syndrome Patients.” Psychiatry Research 200 (2–3): 748–53.
https://doi.org/10.1016/j.psychres.2012.04.041.
Segura-Aguilar, J. 2018. “Dopamine Oxidation and Neurotoxicity.” Journal of Neural Transmission.
Sies, H. 2017. “NRF2 and the Antioxidant Response.” Antioxidants and Redox Signaling.
Verma, Poonam, Alpana Singh, Dominic Ngima Nthenge-Ngumbau, Usha Rajamma, Swagata Sinha, Kanchan Mukhopadhyay, and Kochupurackal P Mohanakumar. 2016.
“Attention Deficit-Hyperactivity Disorder Suffers from Mitochondrial Dysfunction.” BBA Clinical 6: 153–58.
https://doi.org/10.1016/j.bbacli.2016.10.003.